Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell; what started up, ended with another slip and fall

March 14, 2018 6:08pm

The sector opened up, hit an 11:30 a.m. decline, stayed down at the mid-day and closed negative

The algorithms are “ruling” as volatility is the norm affecting negative sentiment

The technical undercurrent of the sector persists

Companies in my pre-open headlights: 3 HITs and 4 MISS (most are being over allocated)

Out and about: Capricor Therapeutics (CAPR) reported a Q4 net income of $12.3 million or +$0.42 (diluted) per share, after reporting a $4.5 million loss in Q4/16. CAPR posted revenue of $475.8 K in Q4/17. For FY17, CAPR reported net income of $2.4 million, or $0.09 per (diluted) share, revenue was reported as $2.7 million. In the final minutes of trading CAPR’s shares hit $1.81; versus $3.00 a year ago. Credit where credit is due as I have been a disbeliever but, lucky, lucky for the forgiveness of CIRM’s loan payable of $15.7 million.

Could'a, wood'a, should have been reading - as a subscriber ...

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.